BioSpace News Archive

PHARMASEAL Launches Second Major Release of EngilityÔ CTMS

PHARMASEAL, a new provider of clinical trial management and governance solutions to enter the market, announces a second major release of its EngilityÔ CTMS platform.

July 8, 2019
·
2 min read
Drug Development

Prestige BioPharma Releases Positive Results from Phase I Study of HD204, Biosimilar Candidate to Bevacizumab

Prestige BioPharma announced positive results from a Phase I clinical trial evaluating the pharmacokinetics, safety and immunogenicity of biosimilar candidate HD204 to Avastin.

July 8, 2019
·
3 min read
Business

Lung Ambition Alliance launches with goal to double five-year survival in lung cancer by 2025

Collaboration prioritizes scientific innovation and social change to one day eliminate lung cancer as a cause of death

July 8, 2019
·
7 min read
Policy

Bellicum Pharmaceuticals Announces Rivo-cel™ Achieves Primary Endpoint in Pediatric Registrational Trial

Primary endpoint of event free survival (EFS) rate at 180 days of 90.9 percent reported for rivo‑cel in BP-004 European registrational trial

July 8, 2019
·
7 min read
Drug Development

Triplet-targeted therapy improves survival for patients with advanced colorectal cancer and BRAF mutations

The three-drug combination of encorafenib, binimetinib and cetuximab significantly improved overall survival in patients with BRAF-mutated metastatic colorectal cancer, according to results of the BEACON CRC Phase III clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.

July 8, 2019
·
5 min read
Business

Evotec and Venture Capital Consortium Form ‘breakpoint Therapeutics GmbH’

Evotec SE announced the formation of Breakpoint Therapeutics GmbH, a spin-off company focusing on the development of Evotec’s DNA damage response (“DDR”) portfolio, comprising discovery-stage assets and drug targets that promise broad therapeutic application in a variety of cancers.

July 8, 2019
·
7 min read
Business

Simbec-Orion Announce Its New Unified Brand Offering

Simbec-Orion, Europe’s leading full-service boutique CRO, announces its new unified brand offering comprising the divisions previously known as Simbec Research, Orion Clinical, Orion Santé and Seirian Laboratories.

July 8, 2019
·
2 min read
Drug Development

sterna biologicals Strengthens Management Team to Progress Towards Phase IIB Development

sterna biologicals GmbH & Co. KG (sterna) announced that the Company has recently appointed Dr. Marion Wencker as consulting Chief Medical Officer and Dr. Thomas Klaue as consulting Chief Financial Officer.

July 8, 2019
·
3 min read
Biotech Beach

Avid Bioservices Enters into Contract Manufacturing Agreements with New and Existing Customers

Company Signs Top Ten Global Pharmaceutical Company as New Client and Expands Relationship with Existing Biotechnology Company Customer

July 8, 2019
·
3 min read
Business

MorphoSys and Vivoryon Therapeutics Enter Agreement on Small Molecule Inhibitors of CD47-SIRP alpha Signaling in Immuno-Oncology

Vivoryon Therapeutics AG and MorphoSys AG today announced that they have entered into an agreement under the terms of which MorphoSys has obtained an exclusive option to license Vivoryon’s small molecule QPCTL inhibitors in the field of oncology.

July 8, 2019
·
8 min read